D
Denali Therapeutics Inc.
DNLI
$15.15
$0.261.75%
D
Sell
8/2/2024Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 8/2/2024 due to an increase in the total return index and valuation index.
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 8/2/2024 due to an increase in the total return index and valuation index.
E
Sell
10/20/2023Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 10/20/2023 due to a decline in the total return index and volatility index.
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 10/20/2023 due to a decline in the total return index and volatility index.
D
Sell
9/21/2023Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 9/21/2023 due to an increase in the volatility index.
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 9/21/2023 due to an increase in the volatility index.
E
Sell
9/6/2023Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 9/6/2023 due to a decline in the total return index and volatility index.
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 9/6/2023 due to a decline in the total return index and volatility index.
D
Sell
8/9/2023Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 8/9/2023 due to a noticeable increase in the solvency index, growth index and valuation index. Total revenue increased 736.98% from $35.14M to $294.12M, the quick ratio increased from 3.3 to 17.22, and earnings per share increased from -$0.8041 to $1.3.
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 8/9/2023 due to a noticeable increase in the solvency index, growth index and valuation index. Total revenue increased 736.98% from $35.14M to $294.12M, the quick ratio increased from 3.3 to 17.22, and earnings per share increased from -$0.8041 to $1.3.
E
Sell
7/25/2023Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 7/25/2023 due to a decline in the volatility index.
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 7/25/2023 due to a decline in the volatility index.
D
Sell
7/6/2023Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 7/6/2023 due to an increase in the total return index, volatility index and valuation index.
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 7/6/2023 due to an increase in the total return index, volatility index and valuation index.
E
Sell
5/30/2023Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 5/30/2023 due to a decline in the valuation index, total return index and volatility index.
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 5/30/2023 due to a decline in the valuation index, total return index and volatility index.
D
Sell
5/15/2023Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index.
Denali Therapeutics Inc. (DNLI) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index.
E
Sell
5/11/2023Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 5/11/2023 due to a decline in the volatility index, total return index and valuation index.
Denali Therapeutics Inc. (DNLI) was downgraded to E+ from D- on 5/11/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell
3/14/2023Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the efficiency index, total return index and solvency index.
Denali Therapeutics Inc. (DNLI) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the efficiency index, total return index and solvency index.
D
Sell
3/2/2022Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to D from D+ on 3/2/2022 due to a significant decline in the growth index, efficiency index and solvency index. The quick ratio declined from 19.18 to 2.29, operating cash flow declined 58.07% from -$41.43M to -$65.49M, and total capital declined 4.75% from $1.08B to $1.03B.
Denali Therapeutics Inc. (DNLI) was downgraded to D from D+ on 3/2/2022 due to a significant decline in the growth index, efficiency index and solvency index. The quick ratio declined from 19.18 to 2.29, operating cash flow declined 58.07% from -$41.43M to -$65.49M, and total capital declined 4.75% from $1.08B to $1.03B.
D
Sell
2/9/2022Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to D+ from C- on 2/9/2022 due to a decline in the total return index and volatility index.
Denali Therapeutics Inc. (DNLI) was downgraded to D+ from C- on 2/9/2022 due to a decline in the total return index and volatility index.
C
Hold
1/25/2022Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to C- from D+ on 1/25/2022 due to an increase in the valuation index and total return index.
Denali Therapeutics Inc. (DNLI) was upgraded to C- from D+ on 1/25/2022 due to an increase in the valuation index and total return index.
D
Sell
12/14/2021Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to D+ from C- on 12/14/2021 due to a noticeable decline in the growth index, total return index and solvency index. Total revenue declined 76.96% from $22.94M to $5.29M, earnings per share declined from -$0.5004 to -$0.6948, and EBIT declined 38.46% from -$61.82M to -$85.59M.
Denali Therapeutics Inc. (DNLI) was downgraded to D+ from C- on 12/14/2021 due to a noticeable decline in the growth index, total return index and solvency index. Total revenue declined 76.96% from $22.94M to $5.29M, earnings per share declined from -$0.5004 to -$0.6948, and EBIT declined 38.46% from -$61.82M to -$85.59M.
C
Hold
9/22/2021Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 9/22/2021 due to a large decline in the total return index.
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 9/22/2021 due to a large decline in the total return index.
C
Hold
9/7/2021Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to C from C- on 9/7/2021 due to a large increase in the total return index.
Denali Therapeutics Inc. (DNLI) was upgraded to C from C- on 9/7/2021 due to a large increase in the total return index.
C
Hold
8/20/2021Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 8/20/2021 due to a decline in the total return index.
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 8/20/2021 due to a decline in the total return index.
C
Hold
8/5/2021Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to C from C- on 8/5/2021 due to a significant increase in the growth index, solvency index and volatility index. Total revenue increased 189.52% from $7.92M to $22.94M, earnings per share increased from -$0.5794 to -$0.5004, and EBIT increased 13.2% from -$71.22M to -$61.82M.
Denali Therapeutics Inc. (DNLI) was upgraded to C from C- on 8/5/2021 due to a significant increase in the growth index, solvency index and volatility index. Total revenue increased 189.52% from $7.92M to $22.94M, earnings per share increased from -$0.5794 to -$0.5004, and EBIT increased 13.2% from -$71.22M to -$61.82M.
C
Hold
7/21/2021Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to C- from D+ on 7/21/2021 due to a substantial increase in the total return index and volatility index.
Denali Therapeutics Inc. (DNLI) was upgraded to C- from D+ on 7/21/2021 due to a substantial increase in the total return index and volatility index.
D
Sell
6/28/2021Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D+ from D on 6/28/2021 due to an increase in the volatility index.
Denali Therapeutics Inc. (DNLI) was upgraded to D+ from D on 6/28/2021 due to an increase in the volatility index.
D
Sell
5/7/2021Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to D from C- on 5/7/2021 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $1.9077 to -$0.5794, EBIT declined 129.18% from $244.08M to -$71.22M, and operating cash flow declined 109.78% from $513.92M to -$50.24M.
Denali Therapeutics Inc. (DNLI) was downgraded to D from C- on 5/7/2021 due to a significant decline in the growth index, solvency index and volatility index. Earnings per share declined from $1.9077 to -$0.5794, EBIT declined 129.18% from $244.08M to -$71.22M, and operating cash flow declined 109.78% from $513.92M to -$50.24M.
C
Hold
4/27/2021Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 4/27/2021 due to a large decline in the total return index and volatility index.
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 4/27/2021 due to a large decline in the total return index and volatility index.
C
Hold
4/12/2021Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to C from C- on 4/12/2021 due to a large increase in the total return index and valuation index.
Denali Therapeutics Inc. (DNLI) was upgraded to C from C- on 4/12/2021 due to a large increase in the total return index and valuation index.
C
Hold
3/25/2021Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 3/25/2021 due to a major decline in the total return index and volatility index.
Denali Therapeutics Inc. (DNLI) was downgraded to C- from C on 3/25/2021 due to a major decline in the total return index and volatility index.
C
Hold
3/2/2021Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to C from D on 3/2/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 597,475.58% from $86 to $513.92M, total revenue increased 3,272.88% from $9.39M to $316.82M, and net income increased 520.56% from -$58.23M to $244.89M.
Denali Therapeutics Inc. (DNLI) was upgraded to C from D on 3/2/2021 due to a significant increase in the growth index, total return index and efficiency index. Operating cash flow increased 597,475.58% from $86 to $513.92M, total revenue increased 3,272.88% from $9.39M to $316.82M, and net income increased 520.56% from -$58.23M to $244.89M.
D
Sell
2/28/2020Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to D from D+ on 2/28/2020 due to a significant decline in the growth index, solvency index and efficiency index. Total revenue declined 65.66% from $13.6M to $4.67M, operating cash flow declined 56.54% from -$30.44M to -$47.64M, and net income declined 16.79% from -$46.26M to -$54.03M.
Denali Therapeutics Inc. (DNLI) was downgraded to D from D+ on 2/28/2020 due to a significant decline in the growth index, solvency index and efficiency index. Total revenue declined 65.66% from $13.6M to $4.67M, operating cash flow declined 56.54% from -$30.44M to -$47.64M, and net income declined 16.79% from -$46.26M to -$54.03M.
D
Sell
2/6/2020Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D+ from D on 2/6/2020 due to a significant increase in the growth index. Total revenue increased 224.14% from $4.2M to $13.6M, operating cash flow increased 29.51% from -$43.18M to -$30.44M, and earnings per share increased from -$0.6109 to -$0.4826.
Denali Therapeutics Inc. (DNLI) was upgraded to D+ from D on 2/6/2020 due to a significant increase in the growth index. Total revenue increased 224.14% from $4.2M to $13.6M, operating cash flow increased 29.51% from -$43.18M to -$30.44M, and earnings per share increased from -$0.6109 to -$0.4826.
D
Sell
5/15/2019Downgrade
Denali Therapeutics Inc. (DNLI) was downgraded to D from D+ on 5/15/2019 due to a significant decline in the growth index, solvency index and valuation index. EBIT declined 155.48% from $76.62M to -$42.51M, earnings per share declined from $0.7932 to -$0.4105, and operating cash flow declined 132.54% from $93.19M to -$30.32M.
Denali Therapeutics Inc. (DNLI) was downgraded to D from D+ on 5/15/2019 due to a significant decline in the growth index, solvency index and valuation index. EBIT declined 155.48% from $76.62M to -$42.51M, earnings per share declined from $0.7932 to -$0.4105, and operating cash flow declined 132.54% from $93.19M to -$30.32M.
D
Sell
3/14/2019Upgraded
Denali Therapeutics Inc. (DNLI) was upgraded to D+ from D on 3/14/2019 due to a significant increase in the growth index, solvency index and total return index. Total revenue increased 10,416.82% from $1.2M to $125.68M, operating cash flow increased 367.6% from -$34.82M to $93.19M, and earnings per share increased from -$0.3776 to $0.7932.
Denali Therapeutics Inc. (DNLI) was upgraded to D+ from D on 3/14/2019 due to a significant increase in the growth index, solvency index and total return index. Total revenue increased 10,416.82% from $1.2M to $125.68M, operating cash flow increased 367.6% from -$34.82M to $93.19M, and earnings per share increased from -$0.3776 to $0.7932.
D
Sell
3/7/2018None
Denali Therapeutics Inc. (DNLI) was downgraded to D from U on 03/07/2018.
Denali Therapeutics Inc. (DNLI) was downgraded to D from U on 03/07/2018.
NASDAQ
03/14/2025 4:00PM Eastern
Quotes delayed
